Biocytogen and Hansoh Pharma Announce an Antibody License Agreement
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. ("Biocytogen", SEHK : 02315) a clinical-stage biotechnology company with a focus on the antibody discovery and development based on its proprietary RenMiceTM Platforms, and Hansoh Pharmaceutical Group Company Limited (“Hansoh Pharma”, SEHK: 3692), a leading innovation-driven pharmaceutical company with a focus on the treatment of major diseases including oncology, infectious diseases, CNS disorders, metabolic diseases and autoimmune diseases, today announced an antibody collaboration, assignment and exclusive license agreement. Biocytogen will provide a license to Hansoh Pharma for their selected fully human antibody molecules against the designated target for the development, manufacturing and commercialization globally. Under the agreement, Biocytogen will receive an upfront payment and will be eligible to receive development and commercial milestones of up to tens of millions of Chinese yuan, as well as single-digit tiered royalties on net sales.
“We are very excited to partner with Hansoh Pharma, one of the largest pharmaceutical companies in China. The licensed antibodies were selected from Biocytogen’s Project Integrum programs and generated from our proprietary fully human antibody RenMiceTM target-knockout mice. The antibodies possess highest possible diversity to improve the success rate of antibody discovery,” said Dr. Yuelei Shen, President and CEO of Biocytogen. “Thanks to Hansoh Pharma’s recognition of our RenMiceTM platforms and Project Integrum. We believe Hansoh Pharma’s strong R&D, manufacturing and commercialization capabilities will accelerate the development of RenMiceTM-derived antibody molecules and bring the benefits to patients worldwide.”
About Project Integrum
Project Integrum is a large-scale antibody drug development project for 1000+ potential drug targets using RenMiceTM (RenMabTM, RenLite® and RenNano®) target knockout mice. Different from the traditional mechanism of action (MOA)-based drug development strategy, Project Integrum uses large-scale in vivo drug efficacy screening methods to discover innovative drugs with excellent safety and efficacy. So far, we have completed making RenMiceTM KO for 1000+ targets. In addition, we have developed a large variety of preclinical antibody assets including 10 fully human bispecific antibodies, 20+ bispecific ADCs, 10+ TCR-mimic antibodies, 30+ monoclonal antibodies against novel targets, and 600+ antibody hits. Antibody molecules generated by Project Integrum have high specificity, high affinity and good druggability, which have attracted many top biopharmaceutical companies to obtain a license or reach a drug co-development agreement with us, including Merck KGaA, ADC Therapeutics, Remgen, NJCTTQ, etc.
About Biocytogen
Biocytogen (HKEX: 02315) is a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies. Using its proprietary RenMabTM/RenLite®/RenNano® mice platforms for fully human monoclonal, bispecific/multispecific antibody and nanobody development, Biocytogen has integrated its in vivo drug efficacy screening platforms and strong clinical development expertise to streamline the entire drug development process. Biocytogen is undertaking a large-scale project to develop first-in-class and/or best-in-class antibody drugs for more than 1000 targets, known as Project Integrum. This project has resulted in 28 drug co-development agreements and 16 RenMiceTM licensing agreements with companies around the world, including several partnerships with multinational pharmaceutical companies (MNCs). Biocytogen's pipeline includes 12 core products, among which two products are in phase II multi-regional clinical trials and two products are in phase I. Headquartered in Beijing, Biocytogen has branches in Haimen Jiangsu, Shanghai, Boston, USA and Heidelberg, Germany. For more information, please visit http://en.biocytogen.com.cn.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230103005498/en/
Contact information
Biocytogen’s Contacts:
Antibody assets and platforms: BD-Licensing@biocytogen.com
Media: pr@bbctg.com.cn
About Business Wire
Business Wire(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Ricardo Helps City of Warsaw to Introduce its First Ever Low Emission Zone28.3.2023 01:01:00 CEST | Press release
Ricardo, a global strategic environmental and engineering consulting company, has won a contract funded by the Clean Air Fund to support the City of Warsaw in Poland to assess the impacts of different Low Emission Zone (LEZ) options so that the city authority, businesses and the public has clear evidence on the costs and benefits for adopting a preferred scheme. Polish cities face severe air quality challenges. In 2018, 36 out of 50 most polluted cities in the European Union (EU) were in Poland. The country’s capital, Warsaw, is one of the most polluted cities – with exposure to air pollution having a health-related cost to society of an estimated €4.2 billion every year. It also has one of the highest vehicle ownership rates (859 per 1,000 people) in Europe and has seen a growing influx of vehicles from outside of the city. This is driven the desire by the city to introduce an ambitious Low Emission Zone in the city by 2024, but doing so in a way that does not disproportionately impac
Everen Declares $200 Million Dividend and Welcomes New Chief Operating Officer27.3.2023 22:59:00 CEST | Press release
Everen Limited (Everen) held its March 2023 Board Meeting on Tuesday, March 21st and its Annual General Meeting (AGM) on Thursday, March 23rd. During the Board Meeting, the directors approved Everen’s 2022 financial statements, discussed the ongoing execution of the 5-year Strategic Plan, and declared a dividend in the aggregate amount of $200 million payable on or before September 29, 2023 to shareholders of record on March 21, 2023. During the AGM, the Shareholders approved technical wording corrections to the Eligibility Requirements and definition of a Nuclear Facility and amended Everen’s Bye-Laws to resolve inconsistencies and elements not required by the Bermuda Companies Act 1981. They also elected a new Board of Directors who will serve for a year ending at the March 2024 AGM. The Shareholders recognized Gail Miller (VP, Human Resources) for her 18 years of service and significant contributions to the organization and also welcomed Robert Foskey into the role of Chief Operatin
Co-Founder John Keppler Rejoins Enviva Inc. as Executive Chairman of the Board27.3.2023 22:46:00 CEST | Press release
Enviva Inc. (NYSE: EVA) (“Enviva,” “our,” “we,” or the “Company”) today announced that John Keppler is returning to the Company as Executive Chairman, effective April 1, 2023. Thomas Meth will continue to lead the Company as President and Chief Executive Officer, and the Company’s interim Chairman, Ralph Alexander, will transition to the role of Lead Independent Director of the Board. Today’s announcement is consistent with the Board of Directors’ (the “Board”) governance plan as announced in November 2022, when Mr. Keppler stepped down from his role as Chairman and CEO of Enviva to address a heart condition. With Mr. Keppler’s recovery and rehabilitation following heart surgery well underway, he is returning to the Company to support his co-founding partner and CEO, Thomas Meth. As Executive Chairman, in cooperation with Mr. Meth, Mr. Keppler is expected to help drive strategic corporate initiatives, growth, and interaction with key capital markets and financial stakeholders. “I am ve
French Blood Establishment (EFS) & Brenus Pharma Partner for the GMP Production of STC-1010, an Innovative Therapy Against Colorectal Cancer27.3.2023 18:00:00 CEST | Press release
The French Blood Establishment (EFS) and Brenus Pharma announce their strategic partnership in the bioproduction of innovative therapy drugs (ITD), highlighting French expertise. This collaboration is part of a shared vision: developing the French bioproduction sector nationally and internationally. EFS’ Cell Therapy and Engineering Unit (UTICELL), based in Saint-Ismier, France, shows recognized expertise in the cell therapy field since 2003 confirmed by a European GMP Certification issued by the ANSM in 2015 for manufacturing, control and storage sites for MTIs. UTICELL also benefits from EFS’ four other certified sites’ expertise. Brenus’s proprietary platform passed key regulatory milestones in 2022 (FDA Pre-IND, EMA Scientific-Advice) and the two synergistic entities have been collaborating effectively for several months to produce GMPs batches through a first scale-up. This public-private partnership aims for a long-term perspective and will lead in 2023 to the production of clini
ETC Group Unveils New Future-Forward Global Brand27.3.2023 17:15:00 CEST | Press release
ETC Group (“ETC”), a leading global value-added distributor for the telecom network and digital infrastructure industry, announced today its intent to rebrand to Netceed. The Group’s brands will integrate into a singular organization across the globe including USTC Corp, Walker, Comstar Supply, and Multicom in the U.S.; EuroTechnoCom in France; ETCP and iETC in Portugal; Comtec in the UK, Qatar, Oman, UAE, and Hong Kong; ILDC in Israel; DNT in the Dominican Republic; ETC Morocco Networks; ETC Germany Networks; Klonex-VCS in Poland; and Tiba Produktions & Vertriebs GmbH in Austria. The unification of the Group reflects the already well-established global reach and local expertise of the companies powered by ETC Group, now coalescing them under one brand worldwide. The transition to the unified global Netceed brand is planned sequentially over six months, starting with its brands in the U.S., France, and the UK. The new name, Netceed, paired with a bold and vibrant new brand design embod